MindRank (www.mindrank.ai) is an AI-driven biotech company with focus on “Undruggable” targets.
The company started operations in 2021 and now consists of 35 scientists with R&D center in China and UK.
The company is led by academicians of the British Royal Society, former R&D scientists from top pharma companies and the global AI competition winners. The team has successful experience in drug R&D and have a large number top publications including Nature Biomedical Engineering, Nature Machine Intelligence, Patterns (Cell Press) etc.
By leveraging its proprietary AI driven drug discovery platform, MindRank has delivered a small molecule Preclinical Candidate (allosteric inhibitor) to a listed biotechnology company in Sept 2021.
In Jan 2022, MindRank begins IND-enabling studies of its proprietary AI-designed drug (Class B GPCR), 8 months after program initiation. Both of the small molecule drugs are expected to enter clinical phase in 2022.
Company Details
- Employees
- 18
- Founded
- -
- Address
- Shanghai, Shanghai, Cn
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.mindrank.ai
- HQ
- Shanghai, Shanghai
Mindrank Ai Questions
Mindrank Ai's website is https://www.mindrank.ai
Mindrank Ai's LinkedIn profile is https://cn.linkedin.com/company/mindrankai
Mindrank Ai has
18 employees.
View email and phone details for 18
employees at Mindrank Ai.
Mindrank Ai's industry is
Biotechnology Research
Mindrank Ai's top competitors are
Anuttacon,
Isomorphic Labs,
Iktos,
Pfizer,
Zhejiang Huahai Pharmaceutical Co., Ltd,
Moleculemind,
Mentor International Group,
Flagship Pioneering,
Aladdin Healthcare Technologies,
Yoltech Therapeutics.
Mindrank Ai's categories are Biotechnology Research
Mindrank Ai's founding year is 2021
